Clinical presentation and outcomes of pre-eclampsia and eclampsia at a national hospital, Kenya: A retrospective cohort study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 13 01 2020
accepted: 02 05 2020
entrez: 6 6 2020
pubmed: 6 6 2020
medline: 18 8 2020
Statut: epublish

Résumé

Hypertensive disorders in pregnancy including pre-eclampsia are associated with maternal and newborn mortality and morbidity. Early detection is vital for effective treatment and management of pre-eclampsia. This study examines and compares the clinical presentation and outcomes between early- and late-onset pre-eclampsia over a two year period. A retrospective cohort study design which examines socio-demographic characteristics, treatment, outcomes, and fetal and maternal complications among women with early onset of pre-eclampsia (EO-PE) and late onset of pre-eclampsia (LO-PE). De-identified records of women who attended antenatal, intrapartum and postnatal care services and experienced pre-eclampsia at Kenyatta National teaching and referral hospital were reviewed. We used chi square, t-test, and calculated odds ratio to determine any significant differences between the EO-PE and LO-PE cohorts. Out of 620 pre-eclamptic and eclamptic patients' records analyzed; 44 percent (n = 273) exhibited EO-PE, while 56 percent had late onset. Women with EO-PE compared to LO-PE had greater odds of adverse maternal and perinatal outcomes including hemolysis elevated liver enzymes and low platelets (HELLP) syndrome (OR: 4.3; CI 2.0-10.2; p<0.001), renal dysfunction (OR; 1.7; CI 0.7-4.1; p = 0.192), stillbirth (OR = 4.9; CI 3.1-8.1; p<0.001), and neonatal death (OR: 8.5; CI 3.8-21.3; p<0.001). EO-PE was also associated with higher odds of prolonged maternal hospitalization, beyond seven days (OR = 5.8; CI 3.9-8.4; p<0.001), and antepartum hemorrhage (OR = 5.8; CI 1.1-56.4; p<0.001). Neonates born after early onset of pre-eclampsia had increased odds of respiratory distress (OR = 17.0; CI 9.0-32.3, p<0.001) and birth asphyxia (OR: 1.9; CI 0.7-4.8; p = 0.142). The profiles and outcomes of women with EO-PE (compared to late onset) suggest that seriousness of morbidity increases with earlier onset. To reduce adverse neonatal and maternal outcomes, it is critical to identify, manage, referral and closely follow-up pregnant women with pre-eclampsia throughout the pregnancy continuum. This study protocol was approved by Population Council's research ethics Institutional Review Board, Protocol 813, and KNH-UoN Ethics and Research Committee, Protocol 293/06/2017.

Sections du résumé

BACKGROUND
Hypertensive disorders in pregnancy including pre-eclampsia are associated with maternal and newborn mortality and morbidity. Early detection is vital for effective treatment and management of pre-eclampsia. This study examines and compares the clinical presentation and outcomes between early- and late-onset pre-eclampsia over a two year period.
METHODS
A retrospective cohort study design which examines socio-demographic characteristics, treatment, outcomes, and fetal and maternal complications among women with early onset of pre-eclampsia (EO-PE) and late onset of pre-eclampsia (LO-PE). De-identified records of women who attended antenatal, intrapartum and postnatal care services and experienced pre-eclampsia at Kenyatta National teaching and referral hospital were reviewed. We used chi square, t-test, and calculated odds ratio to determine any significant differences between the EO-PE and LO-PE cohorts.
RESULTS
Out of 620 pre-eclamptic and eclamptic patients' records analyzed; 44 percent (n = 273) exhibited EO-PE, while 56 percent had late onset. Women with EO-PE compared to LO-PE had greater odds of adverse maternal and perinatal outcomes including hemolysis elevated liver enzymes and low platelets (HELLP) syndrome (OR: 4.3; CI 2.0-10.2; p<0.001), renal dysfunction (OR; 1.7; CI 0.7-4.1; p = 0.192), stillbirth (OR = 4.9; CI 3.1-8.1; p<0.001), and neonatal death (OR: 8.5; CI 3.8-21.3; p<0.001). EO-PE was also associated with higher odds of prolonged maternal hospitalization, beyond seven days (OR = 5.8; CI 3.9-8.4; p<0.001), and antepartum hemorrhage (OR = 5.8; CI 1.1-56.4; p<0.001). Neonates born after early onset of pre-eclampsia had increased odds of respiratory distress (OR = 17.0; CI 9.0-32.3, p<0.001) and birth asphyxia (OR: 1.9; CI 0.7-4.8; p = 0.142).
CONCLUSIONS
The profiles and outcomes of women with EO-PE (compared to late onset) suggest that seriousness of morbidity increases with earlier onset. To reduce adverse neonatal and maternal outcomes, it is critical to identify, manage, referral and closely follow-up pregnant women with pre-eclampsia throughout the pregnancy continuum.
ETHICAL APPROVAL
This study protocol was approved by Population Council's research ethics Institutional Review Board, Protocol 813, and KNH-UoN Ethics and Research Committee, Protocol 293/06/2017.

Identifiants

pubmed: 32502144
doi: 10.1371/journal.pone.0233323
pii: PONE-D-20-01091
pmc: PMC7274433
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0233323

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Integr Blood Press Control. 2016 Jul 27;9:79-94
pubmed: 27555797
Am J Obstet Gynecol. 2013 Dec;209(6):544.e1-544.e12
pubmed: 23973398
Stat Med. 1984 Jul-Sep;3(3):199-214
pubmed: 6385187
BMJ. 2005 Mar 12;330(7491):565
pubmed: 15743856
Am J Epidemiol. 2002 Feb 1;155(3):203-9
pubmed: 11821244
BMC Med Res Methodol. 2018 Nov 15;18(1):132
pubmed: 30442102
Semin Neonatol. 2000 Aug;5(3):197-207
pubmed: 10956445
Acta Obstet Gynecol Scand. 2006;85(5):571-8
pubmed: 16752236
Semin Perinatol. 2009 Jun;33(3):130-7
pubmed: 19464502
J Matern Fetal Neonatal Med. 2017 Dec;30(23):2789-2794
pubmed: 28282780
Arch Dis Child. 1987 Jul;62(7):712-6
pubmed: 3632019
Lancet Glob Health. 2015 Jul;3(7):e387-95
pubmed: 26004775
Clin Obstet Gynecol. 2017 Mar;60(1):141-152
pubmed: 27977436
J Matern Fetal Neonatal Med. 2013 Aug;26(12):1228-33
pubmed: 23413799
Pregnancy Hypertens. 2013 Jan;3(1):44-7
pubmed: 26105740
PLoS One. 2014 Mar 21;9(3):e91198
pubmed: 24657964
Am J Obstet Gynecol. 2012 Jun;206(6):470-5
pubmed: 21963308
BMJ. 2006 Feb 25;332(7539):463-8
pubmed: 16497761
Am J Obstet Gynecol. 2008 Sep;199(3):262.e1-6
pubmed: 18771976
Curr Hypertens Rep. 2014 Sep;16(9):473
pubmed: 25135649
Best Pract Res Clin Obstet Gynaecol. 2011 Aug;25(4):391-403
pubmed: 21333604
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004351
pubmed: 23633317
BMC Pregnancy Childbirth. 2010 Feb 23;10 Suppl 1:S3
pubmed: 20233384
BMJ. 2013 Feb 25;346:f894
pubmed: 23440270
Pregnancy Hypertens. 2013 Oct;3(4):199-202
pubmed: 26103796
Reprod Sci. 2015 Mar;22(3):316-21
pubmed: 25001023
Afr J Reprod Health. 2012 Mar;16(1):35-41
pubmed: 22783666
Obstet Gynecol. 2013 Nov;122(5):1122-1131
pubmed: 24150027
J Reprod Immunol. 2017 Sep;123:12-16
pubmed: 28858635
J Clin Diagn Res. 2014 Sep;8(9):JC01-4
pubmed: 25386463
BMC Pregnancy Childbirth. 2019 Jul 29;19(1):270
pubmed: 31357939
Hypertension. 2018 Jul;72(1):24-43
pubmed: 29899139
F1000Res. 2018 Feb 28;7:242
pubmed: 29560262
Lancet. 2014 Sep 20;384(9948):1129-45
pubmed: 24965816
Arch Gynecol Obstet. 2014 Jul;290(1):53-7
pubmed: 24549271
J Family Med Prim Care. 2017 Oct-Dec;6(4):766-769
pubmed: 29564260
BMC Pregnancy Childbirth. 2018 May 31;18(1):199
pubmed: 29855344
Heart. 2004 Dec;90(12):1499-504
pubmed: 15547046
BMC Pregnancy Childbirth. 2015 Mar 29;15:73
pubmed: 25880924

Auteurs

Charity Ndwiga (C)

Population Council, Nairobi, Kenya.

George Odwe (G)

Population Council, Nairobi, Kenya.

Sripad Pooja (S)

Population Council, Washington, DC, United States of America.

Omondi Ogutu (O)

OBGyn Department, University of Nairobi, Nairobi, Kenya.

Alfred Osoti (A)

OBGyn Department, University of Nairobi, Nairobi, Kenya.

Charlotte E Warren (C)

Population Council, Washington, DC, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH